Furthermore, ezetimibe was found to lower the frequency of Th17 and Th1 cells in RA mice and humans, as well as suppress the differentiation of Th17 cells and the production of pro-inflammatory molecules such as IL-1, IL-17, IFN-γ, TNF-α, and IL-6, thereby slowing the progression of RA (41). The gene discussed is IL17A; the disease is rheumatoid arthritis.